These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 23029050

  • 1. Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma.
    Engesæter B, Engebraaten O, Flørenes VA, Mælandsmo GM.
    PLoS One; 2012; 7(9):e45492. PubMed ID: 23029050
    [Abstract] [Full Text] [Related]

  • 2. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib.
    Luster TA, Carrell JA, McCormick K, Sun D, Humphreys R.
    Mol Cancer Ther; 2009 Feb; 8(2):292-302. PubMed ID: 19174554
    [Abstract] [Full Text] [Related]

  • 3. Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells.
    Engesæter BO, Sathermugathevan M, Hellenes T, Engebråten O, Holm R, Flørenes VA, Mælandsmo GM.
    Cancer Biol Ther; 2011 Jul 01; 12(1):47-58. PubMed ID: 21508672
    [Abstract] [Full Text] [Related]

  • 4. Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines.
    Lillehammer T, Engesaeter BO, Prasmickaite L, Maelandsmo GM, Fodstad O, Engebraaten O.
    J Gene Med; 2007 Jun 01; 9(6):440-51. PubMed ID: 17410615
    [Abstract] [Full Text] [Related]

  • 5. TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors.
    Stadel D, Mohr A, Ref C, MacFarlane M, Zhou S, Humphreys R, Bachem M, Cohen G, Möller P, Zwacka RM, Debatin KM, Fulda S.
    Clin Cancer Res; 2010 Dec 01; 16(23):5734-49. PubMed ID: 20940278
    [Abstract] [Full Text] [Related]

  • 6. Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis.
    Slipicevic A, Øy GF, Rosnes AK, Stakkestad Ø, Emilsen E, Engesæter B, Mælandsmo GM, Flørenes VA.
    Cancer Biol Ther; 2013 Feb 01; 14(2):146-54. PubMed ID: 23192275
    [Abstract] [Full Text] [Related]

  • 7. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.
    Belyanskaya LL, Marti TM, Hopkins-Donaldson S, Kurtz S, Felley-Bosco E, Stahel RA.
    Mol Cancer; 2007 Oct 22; 6():66. PubMed ID: 17953743
    [Abstract] [Full Text] [Related]

  • 8. Delineation of apoptotic genes for synergistic apoptosis of lexatumumab and anthracyclines in human renal cell carcinoma cells by polymerase chain reaction array.
    Jin X, Wu XX, Jin C, Inui M, Sugimoto M, Kakehi Y.
    Anticancer Drugs; 2012 Apr 22; 23(4):445-54. PubMed ID: 22205156
    [Abstract] [Full Text] [Related]

  • 9. Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner.
    Wu XX, Kakehi Y.
    Clin Cancer Res; 2009 Mar 15; 15(6):2039-47. PubMed ID: 19276256
    [Abstract] [Full Text] [Related]

  • 10. Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.
    Liu Y, Hawkins OE, Vilgelm AE, Pawlikowski JS, Ecsedy JA, Sosman JA, Kelley MC, Richmond A.
    Clin Cancer Res; 2015 Dec 01; 21(23):5338-48. PubMed ID: 26152738
    [Abstract] [Full Text] [Related]

  • 11. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
    Zhou L, Wang W, Dicker DT, Humphreys RC, El-Deiry WS.
    Cancer Biol Ther; 2011 Aug 15; 12(4):335-48. PubMed ID: 21785270
    [Abstract] [Full Text] [Related]

  • 12. Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activation.
    Cheng H, Hong B, Zhou L, Allen JE, Tai G, Humphreys R, Dicker DT, Liu YY, El-Deiry WS.
    Cell Cycle; 2012 Sep 01; 11(17):3312-23. PubMed ID: 22895172
    [Abstract] [Full Text] [Related]

  • 13. RIP1 protein-dependent assembly of a cytosolic cell death complex is required for inhibitor of apoptosis (IAP) inhibitor-mediated sensitization to lexatumumab-induced apoptosis.
    Basit F, Humphreys R, Fulda S.
    J Biol Chem; 2012 Nov 09; 287(46):38767-77. PubMed ID: 22927431
    [Abstract] [Full Text] [Related]

  • 14. Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis.
    Abdulghani J, Allen JE, Dicker DT, Liu YY, Goldenberg D, Smith CD, Humphreys R, El-Deiry WS.
    PLoS One; 2013 Nov 09; 8(9):e75414. PubMed ID: 24086526
    [Abstract] [Full Text] [Related]

  • 15. Enhanced metastasis suppression by targeting TRAIL receptor 2 in a murine model of triple-negative breast cancer.
    Malin D, Chen F, Schiller C, Koblinski J, Cryns VL.
    Clin Cancer Res; 2011 Aug 01; 17(15):5005-15. PubMed ID: 21653692
    [Abstract] [Full Text] [Related]

  • 16. Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression.
    Wu XX, Jin XH, Zeng Y, El Hamed AM, Kakehi Y.
    Cancer Sci; 2007 Dec 01; 98(12):1969-76. PubMed ID: 17922852
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
    Ray S, Almasan A.
    Cancer Res; 2003 Aug 01; 63(15):4713-23. PubMed ID: 12907654
    [Abstract] [Full Text] [Related]

  • 19. Synthetic retinoid CD437 induces apoptosis and acts synergistically with TRAIL receptor-2 agonist in malignant melanoma.
    Magnussen GI, Ree Rosnes AK, Shahzidi S, Dong HP, Emilsen E, Engesæter B, Flørenes VA.
    Biochem Biophys Res Commun; 2012 Apr 13; 420(3):516-22. PubMed ID: 22446330
    [Abstract] [Full Text] [Related]

  • 20. Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.
    Milutinovic S, Kashyap AK, Yanagi T, Wimer C, Zhou S, O'Neil R, Kurtzman AL, Faynboym A, Xu L, Hannum CH, Diaz PW, Matsuzawa S, Horowitz M, Horowitz L, Bhatt RR, Reed JC.
    Mol Cancer Ther; 2016 Jan 13; 15(1):114-24. PubMed ID: 26516157
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.